Stockreport

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Verve Therapeutics, Inc.  (VERV) 
PDF BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today an [Read more]